Form 8-K - Current report:
SEC Accession No. 0001641172-25-006504
Filing Date
2025-04-28
Accepted
2025-04-28 17:28:41
Documents
14
Period of Report
2025-04-23
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 33925
2 EX-16.1 ex16-1.htm EX-16.1 4744
  Complete submission text file 0001641172-25-006504.txt   217860

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE kapa-20250423.xsd EX-101.SCH 3027
4 XBRL LABEL FILE kapa-20250423_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE kapa-20250423_pre.xml EX-101.PRE 24173
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3797
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42275 | Film No.: 25881700
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)